Cite
HARVARD Citation
Dignass, A. et al. (n.d.). S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial. American journal of gastroenterology. p. e558. [Online].